Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura

Abstract

We describe a case of refractory thrombotic thrombocytopenic purpura (7 lines of therapy) in which caplacizumab was used over a 6-month period as rescue therapy. Caplacizumab maintained the patient in clinical remission until successful immunosuppression was achieved resulting in normal ADAMTS13 levels. This case illustrates the utility of caplacizumab therapy in treating refractory TTP.

Keywords:

• thrombotic thrombocytopenic purpura
• caplac izumab
• ADAMTS13
• von Willebrand factor

Ethical Statement

This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from the patient in this study for publication of this case report. Institutional approval was not required for this case report.

Disclosure

GMR is a consultant for and reports personal fees from Sanofi. MB declares that she has no conflicts of interest in this work. MF declares that she has no conflicts of interest in this work. JAG declares that he has no conflicts of interest in this work.

Additional information

Funding

No funding was received for this study.